{"id":"vancomycin-inhalation-powder","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dyspnea"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of cell wall precursors, preventing the formation of the bacterial cell wall. This ultimately leads to bacterial cell lysis and death.","oneSentence":"Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:46.038Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of nontuberculous mycobacterial lung disease"}]},"trialDetails":[{"nctId":"NCT03181932","phase":"PHASE3","title":"AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2017-09-20","conditions":"MRSA, Cystic Fibrosis","enrollment":188},{"nctId":"NCT01746095","phase":"PHASE2","title":"Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2013-03","conditions":"Cystic Fibrosis","enrollment":87},{"nctId":"NCT01537666","phase":"PHASE1","title":"Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics","status":"COMPLETED","sponsor":"Savara Inc.","startDate":"2011-11","conditions":"Healthy, Cystic Fibrosis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AeroVanc"],"phase":"phase_3","status":"active","brandName":"Vancomycin inhalation powder","genericName":"Vancomycin inhalation powder","companyName":"Savara Inc.","companyId":"savara-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vancomycin inhalation powder works by inhibiting bacterial cell wall synthesis. Used for Treatment of nontuberculous mycobacterial lung disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}